Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Byrd, John C., Lin, Thomas S., Dalton, James T., Wu, Di, Phelps, Mitch A., Fischer, Beth, Moran, Mollie, Blum, Kristie A., Rovin, Brad, Brooker-McEldowney, Michelle, Broering, Sarah, Schaaf, Larry J., Johnson, Amy J., Lucas, David M., Heerema, Nyla A., Lozanski, Gerard, Young, Donn C., Suarez, Jose-Ramon, Colevas, A. Dimitrios, Grever, Michael R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2007
Matèries:
Plenary Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785084/
https://ncbi.nlm.nih.gov/pubmed/17003373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-05-020735
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars